n.a. (CLTX)

Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)

Deerfield Leads Funding In Creation Of Akari Therapeutics

Deerfield leads the funding in creation of Akari Therapeutics Plc which is created through the Celsus Therapeutics Plc acquisition of Volution Immuno Pharmaceuticals.

Celsus Therapeutics (CLTX) Stock Hits One-Year Low Following Disappointing Trial Results

Shares of Celsus Therapeutics (CLTX) plunged more to a 52-week low in morning trading Tuesday after the biotech company announced the results of its dermatitis treatment in a mid-stage trial.

Celsus Therapeutics Announces That The Phase II Trial Of MRX-6 Cream 2% In Pediatric Atopic Dermatitis Did Not Reach Primary Endpoint

MRX-6 Cream Did Not Demonstrate Separation From Vehicle in Primary Endpoint of Percent Improvement in the Investigator's Global Assessment

Celsus Therapeutics Completes Enrollment Of Phase II Trial Of MRX-6 Cream 2% In Pediatric Atopic Dermatitis

Topline Data From Double-Blind Portion of Trial Expected by End of February, 2015

Celsus Therapeutics Announces FDA Allowance Of IND For Clinical Development Of MRX-6 Cream In Atopic Dermatitis

Phase II Dose Ranging Clinical Trial in Atopic Dermatitis Expected to Begin in First Quarter of 2015